跳至主要内容
临床试验/NCT02521168
NCT02521168已完成3 期

Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia

National Cardiovascular Center Harapan Kita Hospital Indonesia1 个研究点 分布在 1 个国家目标入组 177 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
177
试验地点
1
主要终点
Intubation time

研究概览

简要总结

A condition of decreased serum T3 level in children after cardiac surgery using cardiopulmonary bypass has been commonly recognized as euthyroid sick syndrome (ESS). This syndrome has been closely associated with low cardiac output syndrome after heart surgery. The unique characteristics of pediatric patients with congenital heart disease (CHD) in Indonesia have caused ESS to arise in the population even before surgical managements. Thyroid hormones increase cardiac function, respiration and diuresis. Increased myocardial function occurred through the improvement of mitochondrial effectiveness as the body energy source by utilizing effective energy substrates, lactate and pyruvate. Prevention of decreased serum thyroid hormones level by T3 supplementation could be clinically beneficial. Intravenous T3 unit dose is very expensive and inapplicable for daily use. In adult studies, oral T3 was found to be effective for the prevention of decreased serum T3 levels; similar study on pediatric population, however, has not been elucidated.

详细描述

Methods:

The study was conducted at the cardiac paediatric cardiac intensive care unit of National Cardiovascular Center Harapan Kita. It was performed on paediatric congenital heart disease population who underwent open heart surgery with randomised, double-blind, controlled trial design. All patients with congenital heart disease, 3 years old or less, were included. Types of congenital heart disease suffered required subject to undergo surgery using cardiopulmonary bypass machine with Aristotle score of 6-9. Surgery was aimed for biventricular repair.

The sample size needed almost 200 patients with 50% is in the treatment group. This calculation was based on 90% of patients will be extubated and expected hazard ratio of corresponding treatment group is 1.7 with 5% alpha error and 20% beta error.

Patients were randomised using block randomisation procedure. The stratification factor will be age at the time of recruitment: < 6 weeks old, 6 weeks - 5 months old, > 5 months - 3 years old. Randomization will occur on the day of surgery.

The placebo - saccharum lactis - OR oral T3 (Tetronine, Dalim Biotech Korea) with the dose of 1 mcg per kg body weight were administered via nasogastric tube for every 6 hours starting from the time of anaesthesia induction until 11 doses in total (60 hours after the initial administration). Serial free T3 (FT3) and thyroid stimulating hormone (TSH) measurement were performed starting from the induction of anaesthesia until patient's discharge. Haemodynamics monitoring and echocardiography evaluation was conducted from day 1 to 3 after the surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Day 至 36 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Children undergoing cardiopulmonary bypass
  • Age 36 months old or less
  • Aristotle score 6-9
  • Total correction or biventricular repair

排除标准

  • Single ventricle defects
  • Body weight less than 2 kg at the time of recruitment
  • Presentation with sepsis
  • Tachyarrhythmia or any other arrhythmia before surgery
  • Creatinine level of more than 2 mg/dl
  • Known thyroid disease
  • Known lung abnormalities (including infection) before surgery

研究组 & 干预措施

Oral triiodothyronine

Experimental

Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours

干预措施: Oral triiodothyronine (Drug)

Placebo

Placebo Comparator

Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours

干预措施: Placebo (Drug)

结局指标

主要结局

Intubation time

时间窗: Until patients extubated after surgery in ICU OR died OR still intubated within 7 days

All patients after undergoing congenital heart surgery will be supported by mechanical ventilation. Duration of this support since cross clamp off removal until after surgery will be assessed in the treatment and placebo group. Thyroid supplementation will increase the cardiac function and will make the patients extubated early than the patients without supplementation

次要结局

  • Drug adverse reaction(Every hourly until 12 hours post cross clamp removal, every 3 hours until 24 hours, every 6 hours until 48 hours, every 12 hours until 72 hours post cross clamp removal, and until the patients discharge from hospital)
  • Number of patients with low cardiac output syndrome(6 hours, 12 hours, 18 hours, 24 hours, 48 hours post aortic cross clamp removal)

研究者

发起方
National Cardiovascular Center Harapan Kita Hospital Indonesia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eva M Marwali,MD

MD, PhD

National Cardiovascular Center Harapan Kita Hospital Indonesia

研究点 (1)

Loading locations...

相似试验